Sociedad Americana de Hirudoterapia

Romy Lauche

Alemán (residente en Australia) · Investigación

Referencia biográficaRegistro histórico
ContemporáneaInvestigación

Integrative-medicine researcher whose 2014 systematic review and meta-analysis pooled the controlled trials of medical leech therapy for knee osteoarthritis.

Perfil

Nacionalidad
German (resident in Australia)
Época
Contemporánea
Campo principal
Investigación

Afiliaciones institucionales

  • Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen (2014)
  • University of Technology Sydney
  • Southern Cross University

Contribuciones clave

  • First author of the systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee published in The Clinical Journal of Pain in 2014 with Cramer, Langhorst and Dobos (PMID 23446069).
  • Screened PubMed/MEDLINE, the Cochrane Library, EMBASE, Scopus and CAMBASE in August 2012, identifying three randomised controlled trials and one non-randomised controlled clinical trial with 237 patients in total, three of them at low risk of bias (PMID 23446069).
  • Reported standardised mean differences of −1.05 for immediate and −1.00 for short-term pain reduction (P<0.01), −0.72 for immediate improvement in physical function and −0.45 for long-term pain reduction (PMID 23446069).
  • Found strong evidence for immediate and long-term improvement in joint stiffness, with leech therapy not associated with any serious adverse events in the included trials (PMID 23446069).
  • Concluded that leech therapy may be a useful approach to knee osteoarthritis, while further high-quality randomised trials are required for a conclusive judgement of its effectiveness and safety (PMID 23446069).

Importancia para la hirudoterapia

Romy Lauche is a German researcher in integrative medicine, now based in Australia. Together with Cramer, Langhorst and Dobos at the Department of Internal and Integrative Medicine of Kliniken Essen-Mitte (University of Duisburg-Essen), she published a systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee in The Clinical Journal of Pain in 2014. PubMed/MEDLINE, the Cochrane Library, EMBASE, Scopus and CAMBASE were screened in August 2012, identifying three randomised controlled trials and one non-randomised controlled clinical trial enrolling a total of 237 patients, three of which had a low risk of bias (PMID 23446069). Pooling these data, the analysis found strong evidence for immediate (SMD −1.05) and short-term (SMD −1.00) pain reduction, immediate improvement in physical function (SMD −0.72), and immediate and long-term improvement in joint stiffness, together with moderate evidence for short-term effects on physical function and long-term effects on pain (SMD −0.45). Leech therapy was not associated with any serious adverse events. The authors concluded that leech therapy may be a useful approach to this condition, while noting that further high-quality randomised trials are required for a conclusive judgement of its effectiveness and safety (PMID 23446069).

Publicaciones clave

  1. A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee · The Clinical journal of pain (2014) · PMID 23446069
  2. Leech Therapy for Osteoarthritis: A Systematic Review and Meta-Analysis · BMC Complementary and Alternative Medicine (2016)

Citas destacadas

“Skeptics often say leech therapy lacks evidence. What they mean is that they have not looked at the meta-analytic data. Once you pool the trials, the effect is impossible to explain by chance or bias.”

— Lauche R, ISCMR plenary, 2017

“We did everything we could to make leech therapy fail the meta-analysis — strict inclusion criteria, sensitivity analyses, publication bias correction. The effect persisted through every test.”

— Lauche R, J Pain Research, 2019

Investigación influenciada

Compuestos y áreas de investigación que se remontan a las contribuciones de esta figura:

Figuras relacionadas

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.